J. Goldman & Co’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Hold |
0
| – | – | – | 406 |
|
|
2024
Q4 | – | Sell |
-54,236
| Closed | -$3.15M | – | 405 |
|
|
2024
Q3 | $3.15M | Buy |
54,236
+24,134
| +80% | +$1.4M | 0.09% | 140 |
|
|
2024
Q2 | $1.38M | Buy |
+30,102
| New | +$1.38M | 0.04% | 188 |
|
|
2024
Q1 | – | Sell |
-5,802
| Closed | -$231K | – | 338 |
|
|
2023
Q4 | $231K | Buy |
+5,802
| New | +$231K | 0.01% | 188 |
|
|
2023
Q3 | – | Sell |
-7,677
| Closed | -$308K | – | 296 |
|
|
2023
Q2 | $308K | Buy |
7,677
+355
| +5% | +$14.3K | 0.01% | 204 |
|
|
2023
Q1 | $313K | Sell |
7,322
-16,959
| -70% | -$724K | 0.01% | 205 |
|
|
2022
Q4 | $1.17M | Buy |
24,281
+15,865
| +189% | +$762K | 0.06% | 163 |
|
|
2022
Q3 | $317K | Buy |
+8,416
| New | +$317K | 0.02% | 223 |
|